• Home
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Pharmacy Solutions
RxWiki - Home
Find a Pharmacy Health News Medications Conditions RxCoupons Pharmacy Solutions

FDA Alerts

FDA Approves Children's Brain Tumor Drug
The US Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma (SEGA).
Afinitor for Non-Cancerous Kidney Tumors
The U.S. Food and Drug Administration approved Afinitor ( everolimus ), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas ) not requiring immediate surgery in patients with tuberous sclerosis complex ( TSC ).
FDA approves new treatment for rare type of pancreatic cancer
On Thursday, the U.S. Food and Drug Administration (FDA) approved Afinitor ( everolimus ) to treat patients with progressive neuroendocrine tumors located in the pancreas ( PNET ) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

REFINE

  • medications
      • (-) Remove Afinitor filter Afinitor
  • conditions
      • Cancer (2) Apply Cancer filter
        • Brain Cancer (1) Apply Brain Cancer filter
        • Pancreatic Cancer (1) Apply Pancreatic Cancer filter
      • Kidney Disease (1) Apply Kidney Disease filter
      • Pediatrics (1) Apply Pediatrics filter
All information on this site is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk.
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Mobile App
  • Pharmacy Solutions
  • Terms and Conditions
  • Privacy Policy
  • Contact
  • Home
    Facebook
  • Home
    Google Plus
  • Home
    Twitter
© 2020 Digital Pharmacist Inc.